Medical marijuana is causing a stir as patients petition for access to cannabis-derived compounds for medicinal purposes, while governments worldwide seek to control the supply of the still-illegal plant. However, biochemists at the Technical University of Dortmund in Germany may have a solution to this conundrum — THC-producing yeast. These genetically-modified organisms are potentially capable of synthesizing THC, and other medically important marijuana compounds, using an affordable method which can be scaled for bulk production.
The team at the Technical University of Dortmund in Germany published the details on their THC-producing yeast in a recent issue of the scientific journal, Biotechnology Letters. The process used the gene for tetrahydrocannabinolic acid (THCA) synthase, an enzyme responsible for the production of THC, and expressed it in two strains of yeast. Using these strains, the team was able to produce small amounts of THC and cannabidiol, another medically active compound found in marijuana which is used to treat epilepsy and other diseases. With the help of THC Pharm of Frankfurt, biochemist Oliver Kayser hopes to increase production to an industrial level, while also hoping to duplicate the entire chemical pathway of THC production, not just the final stage.
Researchers from Germany’s Technical University of Dortmund are not the only ones interested in using yeast to make marijuana compounds. Scientists from England’s Anandia Laboratories and Canada’s Hyasynth Bio are also hard at work developing their own strains of THC-producing yeast. However, these teams already have some stiff competition from an unexpected source — the marijuana plant itself. Some strains of the marijuana plant are bursting with THC, with up to 30 percent THC per dry weight. Called the “the Ferrari of the plant world” by Anandia Laboratories founder Dr. Jonathan Page, it appears the marijuana plant is hard to beat.
Researchers are not giving up on genetic engineering, though. The production of THC from yeast is desirable as it makes THC affordable and easy to obtain, clearly a win-win situation for both patients and scientists. Patients who need THC could purchase the less expensive form of the chemical derived from yeast instead of opting for chemically synthesized pills, which tend to be expensive for consumers. It also spares patients and scientists from the complicated issue of growing and obtaining medical marijuana plants. Yeast production also may improve access to THC and marijuana’s other medically-important constituents, making it possible to test the medical effectiveness of THC, cannabidiol, and other chemicals in both animal and human studies.
San Francisco startup Dimensional advertised for people to walk robot dogs through city streets. The New York Times reported that the job could include carrying a roughly 33-pound robot back to the office if it overheated. A lift home is an awkward requirement for a labor-saving machine.
Keeping the hardware running is only one challenge. Anthropic's robotics tests found that language models mostly failed when controlling joints directly, but did better when directing trained controllers. Giving an AI agent a body doesn't teach it to handle ordinary household objects.
Soon, a mattress protector may be more than a bed cover. Australian medtech company Sleeptite and researchers at RMIT University have received a US patent for FlexiSense, a smart bedding technology that tracks body position and posture to help caregivers identify when older residents may be at risk of falling.
The technology is being developed for Sleeptite’s in-bed monitoring system, REMi, and was recently on display at The MedTech Conference in Boston. A peer-reviewed study in Flexible and Printed Electronics says the sensors can also be made at scale without sacrificing performance or durability.
AI companies spend enormous amounts of time convincing us their technology is safe and secure. But what happens when those same companies become targets of increasingly sophisticated AI-powered attacks? Anthropic, the company behind Claude, is now facing that question. According to a Washington Post report, cybersecurity startup Cathedral discovered vulnerabilities that let its researchers access sensitive information in Anthropic's internal systems.
The researchers used AI agents to identify potential entry points in less than 12 hours. Interestingly, they didn't need to crack Claude itself. Instead, they exploited weaknesses in third-party business applications that Anthropic uses for everyday operations. Anthropic's security testing program disclosed the findings, which allows outside researchers to identify and report vulnerabilities.